GPIHBP1 Autoantibody ELISA
- SKU:
- 27267
- Bulk Pricing:
-
- Buy 5 - 20 and get 5% off
- Buy 21 - 30 and get 10% off
- Buy 31 - 50 and get 15% off
- Buy 51 or more – call for best pricing
The cookie settings on this website are set to 'allow all cookies' to give you the very best experience. Please click Accept Cookies to continue to use the site.
Indirect ELISA for the determination of human GPIHBP1 Autoantibody in serum, EDTA-plasma, heparin plasma, and post-heparin EDTA-plasma.
GPIHBP1 (Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1) is an anchor protein that is modified by glycolipid and it has been known that it exists on a capillary endothelial cell membrane and involves with metabolism of triglyceride rich (TG-rich) lipoprotein (triglyceride).
GPIHBP1 transports lipoprotein lipase (LPL) synthesized and secreted in adipocyte or skeletal muscle cells into capillary lumen by transcytosis and it binds LPL on the surface of endothelial cells so that GPIHBP1 has an critical role for metabolizing TG-rich lipoprotein.
It has been already know that type I hyperlipemia (hyperchylomicronemia) can be caused by GPIHBP1 gene mutation, however, the new insight regarding existence of GPIHBPI autoantibody as a novel pathological unit has been reported on the following paper published by New England Journal of Medicine (NEJM).
According to the new insight, GPIHBP1 antibody against to GPIHBP1 protein interferes the binding between GPIHBP1 and LPL, then it blocks the transport of LPL by GPIHBP1. At the end, severe hyperchylomicronemia is caused by the phenomenon as same as gene mutation.
Indirect ELISA for the determination of human GPIHBP1 Autoantibody in serum, EDTA-plasma, heparin plasma, and post-heparin EDTA-plasma.
GPIHBP1 (Glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1) is an anchor protein that is modified by glycolipid and it has been known that it exists on a capillary endothelial cell membrane and involves with metabolism of triglyceride rich (TG-rich) lipoprotein (triglyceride).
GPIHBP1 transports lipoprotein lipase (LPL) synthesized and secreted in adipocyte or skeletal muscle cells into capillary lumen by transcytosis and it binds LPL on the surface of endothelial cells so that GPIHBP1 has an critical role for metabolizing TG-rich lipoprotein.
It has been already know that type I hyperlipemia (hyperchylomicronemia) can be caused by GPIHBP1 gene mutation, however, the new insight regarding existence of GPIHBPI autoantibody as a novel pathological unit has been reported on the following paper published by New England Journal of Medicine (NEJM).
According to the new insight, GPIHBP1 antibody against to GPIHBP1 protein interferes the binding between GPIHBP1 and LPL, then it blocks the transport of LPL by GPIHBP1. At the end, severe hyperchylomicronemia is caused by the phenomenon as same as gene mutation.